Pemphigus - Pipeline Review, H2 2015 - 8 Companies & 10 Drug Profiles

. Buy Forskohlii online About Phenergan (Promethazine) without prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/6sdzrj/pemphigus) has announced the addition of the "Pemphigus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. http://future-pharmaceuticals.blogspot.com Buy Halonix without Rx About Dexone (Dexamethasone) It also reviews key players involved in the therapeutic development for Pemphigus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Detrol La (Tolterodine) with no prescription Rheumatrex (Methotrexate) without Rx It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development Almirall, S.A. Biogen, Inc. Genmab A/S HanAll Biopharma Co., Ltd. Immunomedics, Inc. Momenta Pharmaceuticals, Inc. Novartis AG PinCell srl Drug Profiles ADP-31415 Antibody for Autoimmune Disorders and Inflammation DP-C006 HL-161 ofatumumab PC-111 rituximab T-Cell Therapy for Pemphigus Vulgaris VAY-736 veltuzumab For more information visit .researchandmarkets.com/research/6sdzrj/pemphigus

Dako, an Agilent Technologies Company, Announces FDA Approval of New Test for Lung Cancer Patients

CARPINTERIA, Calif.--(BUSINESS WIRE)--Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. About Cialis Super Force (Tadalafil + Dapoxetine) with free prescription Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC. Dako developed the diagnostic, known as PD-L1 IHC 28-8 pharmDx, through a collaboration with Bristol-Myers Squibb, the maker of OPDIVO®, an immuno-oncology therapy approved by the FDA for the treatment of all patients with previously treated NSCLC. Buy Tadacip (Tadalafil) with free prescription The diagnostic was used to assess PD-L1 expression in the Phase 3 CheckMate 057 trial, in which OPDIVO® demonstrated superior overall survival in patients with previously treated metastatic non-squamous NSCLC compared to chemotherapy. Buy Phoslo (Calcium Acetate) without prescription The FDA today expanded the indication for OPDIVO® to include previously treated non-squamous NSCLC in addition to the squamous NSCLC indication. Lung cancer is the leading cause of cancer-related deaths worldwide. Buy Glez Historically, the one-year overall survival in the second-line treatment of NSCLC has been about 26 percent. “Immuno-oncology is an important area within cancer treatment, and we are excited about Agilent’s involvement in these advancements and the potential PD-L1 IHC 28-8 pharmDx has in helping to provide information to oncologists considering OPDIVO for patients with non-squamous non-small cell lung cancer,” said Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group. “We are proud to announce the recent FDA approval of OPDIVO based upon overall survival in an expanded indication for all appropriate patients with previously treated metastatic non-small cell lung cancer,” added Michael Giordano, senior vice president and head of Development, Oncology, at Bristol-Myers Squibb. About Esidrix (Hydrochlorothiazide) without Rx “Our collaboration with Dako underscores our leadership in cancer innovation and our commitment to advancing research evaluating the potential role of PD-L1 in multiple tumor types.” PD-L1 IHC 28-8 pharmDx is the first and only diagnostic assay approved to assess the survival benefit associated with OPDIVO®. Buy Eucalyptus Oil online PD-L1 testing is not required for the use of OPDIVO®, but it may provide additional information for physicians and inform patient dialogue. Dako is a worldwide leader in partnering with pharmaceutical companies to develop immunohistochemical-based diagnostics for cancer therapy. About Agilent Technologies and Dako Agilent Technologies Inc. http://medical-questions-answers.blogspot.com (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.0 billion in fiscal 2014 and employs about 12,000 people worldwide. Agilent marks its 50th anniversary in analytical instrumentation this year. In 2012, Agilent acquired Dako, a well-known provider of reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Information about Agilent is available at .agilent.com and information about Dako products is available here. NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at .agilent.com/go/news.

Global Drug Delivery in Cancer Market Study 2015-2024 - Updated Technologies, Markets and Companies Analysis

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/qczqdj/drug_delivery_in) has announced the addition of Jain PharmaBiotech s new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering. The market value of drug delivery technologies and the anticancer drugs are difficult to separate. About Aygestin (Norethisterone Bp) without Rx Cancer market estimates from 2014-2024 are given according to organs involved and the types of cancer as well as according to technologies. About Viagra Capsules (Sildenafil Citrate) with free Rx Distribution of the into major regions is also described. Innovative cancer therapies are based on current concepts of molecular biology of cancer. Buy Differin (Adapalene) with free prescription These include antiangiogenic agents, immunotherapy, bacterial agents, viral oncolysis, targeting of cyclic-dependent kinases and tyrosine kinase receptors, antisense approaches, gene therapy and combination of various methods. About Frumil with free prescription Important methods of immunotherapy in cancer involve use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy. Several innovative methods of drug delivery are used in cancer. Glucophage SR (Metformin) with no prescription These include use of microparticles as carriers of anticancer agents. Buy Diabetes online These may be injected into the arterial circulation and guided to the tumor by magnetic field for targeted drug delivery. http://webmd-board.blogspot.com Polyethylene glycol (PEG) technology has been used to overcome some of the barriers to anticancer drug delivery. Encapsulating anticancer drugs in liposomes enables targeted drug delivery to tumor tissues and prevents damage to the normal surrounding tissues. Monoclonal antibodies can be used for the delivery of anticancer payloads such as radionucleotides, toxins and chemotherapeutic agents to the tumors. Antisense oligonucleotides have been in clinical trials for cancer for some time now. RNAi has also been applied in oncology. Small interfering RNAs (siRNAs) can be targeted to tumors and one example is suppression of H-ras gene expression indicating the potential for application in therapy of ovarian cancer. Cancer gene therapy is a sophisticated form of drug delivery for cancer. Various technologies and companies developing them are described. Nucleic acid-based cancer vaccines are also described. Drug delivery strategies vary according to the type and location of cancer. Role of drug delivery in the management of cancers of the brain, the bladder, the breast, the ovaries and the prostate are used as examples to illustrate different approaches both experimental and clinical. Biodegradable implants of carmustine are already used in the treatment of malignant brain tumors. Profiles of 231 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 266 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 67 tables and 11 figures. Key Topics Covered: Part I: Technologies & Markets Executive Summary 1. Introduction to cancer therapy 2. Innovative treatments for cancer 3. Drug delivery systems for cancer 4. Delivery of Biological Therapies for Cancer 5. Delivery strategies according to cancer type and location 6. Cancer drug delivery markets 7. References Part II: Companies 8. Companies involved in cancer drug delivery For more information visit .researchandmarkets.com/research/qczqdj/drug_delivery_in Source: Jain PharmaBiotech